Home > Publications Database > Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia. > print

001     169191
005     20240221132057.0
024 7 _ |a 10.1016/j.bbr.2022.114276
|2 doi
024 7 _ |a pmid:36574844
|2 pmid
024 7 _ |a 0166-4328
|2 ISSN
024 7 _ |a 1872-7549
|2 ISSN
024 7 _ |a altmetric:140631224
|2 altmetric
037 _ _ |a DZNE-2023-00070
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Felgel-Farnholz, Viktoria
|b 0
245 _ _ |a Adolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia.
260 _ _ |a Amsterdam
|c 2023
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1708517999_22071
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The existence of sex differences in schizophrenia is a well documented phenomenon which led to the hypothesis that female sex hormones are neuroprotective and hence responsible for the more favorable disease characteristics seen in women. The current study sought to investigate the effects of estrogen-like agents administered during early adolescence on behavioral outcomes in adulthood using the neurodevelopmental maternal immune activation (MIA) rodent model of schizophrenia. Female MIA offspring were administered during the asymptomatic period of adolescence with either 17β-estradiol, raloxifene or saline and were tested in late adolescence and adulthood for schizophrenia-related behavioral performance. We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Raloxifene Hydrochloride
|0 4F86W47BR6
|2 NLM Chemicals
650 _ 7 |a Morris Water Maze (MWM)
|2 Other
650 _ 7 |a Poly I:C
|2 Other
650 _ 7 |a Preventive hormonal treatment
|2 Other
650 _ 7 |a Raloxifene
|2 Other
650 _ 7 |a estradiol
|2 Other
650 _ 7 |a schizophrenia
|2 Other
650 _ 7 |a Poly I-C
|0 O84C90HH2L
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Raloxifene Hydrochloride: pharmacology
|2 MeSH
650 _ 2 |a Schizophrenia: complications
|2 MeSH
650 _ 2 |a Schizophrenia: drug therapy
|2 MeSH
650 _ 2 |a Rodentia
|2 MeSH
650 _ 2 |a Poly I-C: pharmacology
|2 MeSH
650 _ 2 |a Behavior, Animal: physiology
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Prenatal Exposure Delayed Effects
|2 MeSH
650 _ 2 |a Cognition
|2 MeSH
700 1 _ |a Hlusicka, Elizabeth Barroeta
|b 1
700 1 _ |a Edemann-Callesen, Henriette
|b 2
700 1 _ |a Garthe, Alexander
|0 P:(DE-2719)2810535
|b 3
|u dzne
700 1 _ |a Winter, Christine
|b 4
700 1 _ |a Hadar, Ravit
|b 5
773 _ _ |a 10.1016/j.bbr.2022.114276
|g p. 114276 -
|0 PERI:(DE-600)2013604-3
|p 114276
|t Behavioural brain research
|v 441
|y 2023
|x 0166-4328
856 4 _ |u https://pub.dzne.de/record/169191/files/DZNE-2023-00070_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/169191/files/DZNE-2023-00070_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:169191
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2810535
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2023
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2022-11-17
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-17
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-17
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BEHAV BRAIN RES : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-22
920 1 _ |0 I:(DE-2719)1740001
|k AG Garthe
|l Technology Platform Neurobiology of Behaviour
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1740001
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21